- First therapeutic approved for the treatment of aTTP, a rare blood-clotting disorder
- In addition, U.S. FDA to conduct priority review of caplacizumab with a target action date of February 6, 2019
PR Newswire
BRIDGEWATER, N.J., Sept. 3, 2018
PR Newswire
BRIDGEWATER, N.J., Sept. 3, 2018
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey